Please login to the form below

Not currently logged in
Email:
Password:

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

Boehringer Ingelheim headquarters

Boehringer Ingelheim will next week mark another milestone in its oncology ambitions when it launches its first cancer drug in the US.

Gilotrif (afatinib) received FDA approval in July to treat patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations.

The personalised cancer drug was approved alongside a companion diagnostic developed by Qiagen to detect the presence of EGFR mutations.

Boehringer plans to support the launch of Gilotrif with a “comprehensive patient support programme” of access and clinical support services, including financial support.

Gilotrif's passage through the FDA regulatory process was a relatively speedy one, with the drug granted priority review in January this year due to the urgent need for new treatments in NSCLC, which accounts for about 85 per cent of all lung cancers.

In Europe, where it is set to be branded as Giotrif, afatinib last month received the backing of EMA scientific advisors at the Committee for Healthcare and Medical Products, putting it on course for full approval by December.

The company is also investigating the drug in breast cancer and head and neck cancer, while elsewhere its oncology pipeline includes the angiogenesis inhibitor nintedanib, in phase III trials for NSCLC and ovarian cancer, and polo-like kinase 1 (Plk1) inhibitor volasertib, which is in phase II testing for acute myeloid leukaemia.

Article by
Dominic Tyer

29th August 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics